NY Federal Court Won't Rethink Cymbalta Labeling Suit

Law360, New York (February 26, 2015, 4:18 PM EST) -- A New York federal judge on Thursday declined to review a suit against Eli Lilly & Co. over the labeling of its antidepressant Cymbalta that allegedly downplays its withdrawal symptoms, finding that the plaintiff had not introduced any new evidence that warranted a new look at the case.

U.S. District Judge Robert Sweet denied a motion by plaintiff Jesse McDowell to reconsider his summary judgment ruling for Eli Lilly, saying expert reports he had submitted since the ruling did not contain any new information that was not public when he tossed the case in November.

Judge Sweet said, for example, that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!